Leerink Partners Maintains a Hold Rating on Amneal Pharmaceuticals (AMRX)

Leerink Partners analyst Ami Fadia maintained a Hold rating on Amneal Pharmaceuticals (AMRXResearch Report) on February 26. The company’s shares closed last Tuesday at $5.30.

According to TipRanks.com, Fadia is a 3-star analyst with an average return of 6.7% and a 51.1% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.

Currently, the analyst consensus on Amneal Pharmaceuticals is a Moderate Buy with an average price target of $6.50, a 24.3% upside from current levels. In a report issued on February 26, Raymond James also reiterated a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Amneal Pharmaceuticals’ market cap is currently $764.7M and has a P/E ratio of 11.70. The company has a Price to Book ratio of -0.51.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.